Merck emphasized the broader significance of the findings
This study evaluated a difficult-to-treat Crohn's disease patient population
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
Subscribe To Our Newsletter & Stay Updated